The present disclosure concerns methods of using novel bacterial strains of 0617-T307, 0917-T305, 0917-T306, 0917-T307, 0118-T319, 0318-T327, and 0418-T328, the cell broth and novel metabolites produced from the bacterial strains, that can inhibit the growth of a variety of fish pathogens. The methods include use of novel, potent antimicrobial metabolites produced from the strains corresponding to a compound having Formula (I):
1. A method of controlling a fish pathogen and associated disease of a fish, comprising the steps of
(i) producing a composition from Pseudomonas soli or Pseudomonas mosselii comprising a bacterial metabolite of Formula (I)
and
(ii) applying said composition to the fish to inhibit the growth of the fish pathogen and the associated disease on the fish.
2. The method of claim 1 , wherein the fish pathogen is selected from the group consisting of Aeromonas salmonicida, Streptococcus agalactiae, Streptococcus iniae, Vibrio parahaemolyticus, Saprolegnia parasitica , and Tenacibaculum maritimum.
3. The method according to claim 1 , wherein the associated disease is selected from the group consisting of fish columnaris disease, furunculosis, streptococcosis, vibriosis, acute hepatopancreatic necrosis disease, saprolegniasis, and tenacibaculosis.
4. The method according to claim 1 , wherein the fish is selected from the group consisting of fresh-water fish and sea-water fish.
5. A method of controlling a fish pathogen disease, comprising:
applying a composition comprising between about 1.0×10 5 and 1.0×10 9 cfu per mL Pseudomonas bacteria to fish to inhibit the growth of a fish pathogen and an associated disease,
wherein the Pseudomonas bacteria is selected from the group consisting of Pseudomonas soli and Pseudomonas mosselii.
6. The method of claim 5 , wherein the Pseudomonas bacteria is selected from the group consisting of Pseudomonas soli 0617-T307 (Accession No. PTA-126796), Pseudomonas soli 0917-T305 (Accession No. PTA-126797), Pseudomonas soli 0917-T306 (Accession No. PTA-126798), Pseudomonas soli 0917-T307 (Accession No. PTA-126799), Pseudomonas mosselii 0118-T319 (Accession No. PTA-126800), Pseudomonas mosselii 0318-T327 (Accession No. PTA-126801), and Pseudomonas mosselii 0418-T328 (Accession No. PTA-126802).
7. The method according to claim 5 , wherein the composition comprises between about 5.0×10 7 and 2.0×10 8 cfu per mL Pseudomonas bacteria.
8. The method of claim 5 , wherein the fish pathogen is selected from the group consisting of Flavobacterium columnare, Aeromonas salmonicida, Streptococcus agalactiae, Streptococcus iniae, Vibrio parahaemolyticus, Saprolegnia parasitica , and Tenacibaculum maritimum.
9. The method according to claim 5 , wherein the associated disease is selected from the group consisting of furunculosis, streptococcosis, vibriosis, acute hepatopancreatic necrosis disease, saprolegniasis, and tenacibaculosis.
10. The method according to claim 5 , wherein the fish is selected from the group consisting of fresh-water fish and sea-water fish.
11. The method according to claim 5 , wherein the fish is selected from the group consisting of wild fish and farm fish.
12. The method according to claim 5 , wherein the fish is selected from the group consisting of Salmon, Trout, Cyprinids, Pike, Perch, Bullheads, Turbot, and Halibut.
13. The method according to claim 1 , wherein the fish is selected from the group consisting of wild fish and farm fish.
14. The method according to claim 1 , wherein the fish is selected from the group consisting of Salmon, Trout, Cyprinids, Pike, Perch, Bullheads, Turbot, and Halibut.
15. The method of claim 1 , wherein the composition is produced from a Pseudomonas soli or Pseudomonas mosselii bacteria is selected from the group consisting of Pseudomonas soli 0617-T307 (Accession No. PTA-126796), Pseudomonas soli 0917-T305 (Accession No. PTA-126797), Pseudomonas soli 0917-T306 (Accession No. PTA-126798), Pseudomonas soli 0917-T307 (Accession No. PTA-126799), Pseudomonas mosselii 0118-T319 (Accession No. PTA-126800), Pseudomonas mosselii 0318-T327 (Accession No. PTA-126801), and Pseudomonas mosselii 0418-T328 (Accession No. PTA-126802).
16. A method of controlling a pathogen and associated disease of a crustacean or a mollusk comprising the steps of
(i) producing a composition from Pseudomonas soli or Pseudomonas mosselii comprising a Pseudomonas bacterial metabolite as Formula (I)
and
(ii) applying said composition to the crustacean or mollusk to inhibit the growth of the pathogen and the associated disease on the crustacean or mollusk.
17. The method of claim 16 , wherein the pathogen is selected from the genera of Vibrio.
18. The method according to claim 16 , wherein the associated disease is vibriosis, acute hepatopancreatic necrosis disease, or contamination in the crustacean and mollusk.
19. The method according to claim 16 , wherein the crustacean is selected from the group consisting of shrimp and crab.
20. The method according to claim 16 , wherein the mollusk is selected from the group consisting of oyster, conch, and squid.
21. The method according to claim 16 , wherein the Pseudomonas soli or Pseudomonas mosselii is selected from the group consisting of Pseudomonas soli 0617-T307 (Accession No. PTA-126796), Pseudomonas soli 0917-T305 (Accession No. PTA-126797), Pseudomonas soli 0917-T306 (Accession No. PTA-126798), Pseudomonas soli 0917-T307 (Accession No. PTA-126799), Pseudomonas mosselii 0118-T319 (Accession No. PTA-126800), Pseudomonas mosselii 0318-T327 (Accession No. PTA-126801), and Pseudomonas mosselii 0418-T328 (Accession No. PTA-126802).